Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer : outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with partially platinum-sensitive relapse [6-12 months platinum-free interval (PFI)] is unclear. Patients and methods: Within OVA-301, we therefore now report on the outcomes for the 214 cases in this subgroup. Results: Trabectedin/PLD resulted in a 35% risk reduction of disease progression (DP) or death [hazard ratio (HR) = 0.65, 95% confidence interval (CI), 0.45-0.92; P = 0.0152; median progression-free survival (PFS) 7.4 versus 5.5 months], and a significant 41% decrease in the risk of death (HR = 0.59; 95% CI, 0.43-0.82; P = 0.0015; median survival 23.0 versus 17.1 months). The safety of trabectedin/PLD in this subset mimicked that of the overall population. Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), although patients in the trabectedin/PLD arm had a slightly lower proportion of further platinum (49% versus 55%). Importantly, patients in the trabectedin/PLD arm survived significantly longer after subsequent platinum (HR = 0.63; P = 0.0357; median 13.3 versus 9.8 months). Conclusion: This hypothesis-generating analysis demonstrates that superior benefits with trabectedin/PLD in terms of PFS and survival in the overall population appear particularly enhanced in patients with partially sensitive disease (PFI 6-12 months).

Vergote, I. (författare)
Tjulandin, S. (författare)
Kong, B. (författare)
Roy, M. (författare)
Chan, S. (författare)
Filipczyk-Cisarz, E. (författare)
Hagberg, HansUppsala universitet,Enheten för onkologi(Swepub:uu)hanshagb (författare)
Kaye, S. B. (författare)
Colombo, N. (författare)
Lebedinsky, C. (författare)
Parekh, T. (författare)
Gomez, J. (författare)
Park, Y. C. (författare)
Alfaro, V. (författare)
Monk, B. J. (författare)
Uppsala universitetEnheten för onkologi (creator_code:org_t)

Av författaren/redakt...: Poveda, A.; Vergote, I.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; visa fler...; Filipczyk-Cisarz ...; Hagberg, Hans; Kaye, S. B.; Colombo, N.; Lebedinsky, C.; Parekh, T.; Gomez, J.; Park, Y. C.; Alfaro, V.; Monk, B. J.; visa färre...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.